Possibilities of cognitive-affective disorders correction in patients with atopic dermatitis using selanc regulatory peptide
| Autor: | Larisa N. Borzunova, L. S. Kruglova, Nataliya A. Voron'kova, Lyubov' A. Novikova, Elena V. Dontsova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Курский научно-практический вестник «Человек и его здоровье». :84-89 |
| ISSN: | 1998-5754 1998-5746 |
| Popis: | Objective: To evaluate the efficacy of the selank regulatory peptide against cognitive-affective disorders in patients with atopic dermatitis (AD). Material and methods. The analysis of cognitive-affective disorders of 65 patients with atopic dermatitis (AD), randomized into 2 statistically comparable groups, was carried out. Patients of the first group received basic drug therapy (BT) for AD, the second group - a combination of selank and BT (S + BT) intranasally, 2 drops in each nasal passage, 3 times a day, for 14 days. The control group consisted of 30 healthy individuals. The levels of personal (LT) and reactive (RT) anxiety, alexithymia, the level of β-endorphin in the blood, and the quality of life (QOL) before treatment and after 30 days from its start were assessed. Results. In patients with AD, the level of RT was 4.2 times higher than in the control group, RT - 3.2 times, alexithymia - 18 times. In the BT group, 30 days after the start of treatment, RT decreased 1.4 times and RT - 1.3 times. In the C+BT group, the decrease in LT and RT was equally significant - by 2.4 times. The levels of alexithymia and blood β-endorphin in the BT group did not change significantly. In the S+BT group, alexithymicity of patients decreased by 1.2 times, and the level of β-endorphin in the blood increased by 1.9 times. The quality of life index in the BT group decreased 1.2 times after 30 days from the start of therapy, and 1.7 times in the S + BT group. Conclusion. Patients with AD are characterized by the increased levels of personal and reactive anxiety and alexithymia, which reduce their quality of life. The use of the selank regulatory peptide in the complex treatment of patients with AD has a corrective effect on affective-cognitive impairment, contributing to a decrease in the levels of personal and reactive anxiety, alexithymia, increases the level of β-endorphin in the blood and improves the quality of life of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|